Business Update
Cerus up following cancer vaccine news
Published in Vaccine Weekly, October 13th, 2004
Shares of the Concord-based drug developer closed at $2.47, up 36 cents or 17%, on the Nasdaq Stock Market. The stock set a 52-week high of $5.50 on April 21 and a year-low of $1.60 on July 23.
The vaccine has been shown in studies to prolong survival of tumor-bearing mice.
The studies were published in September 21, 2004,'s issue of Proceedings of the National Academy of Sciences.
Cerus said its goal is still to file its first cancer vaccine investigational new drug application by the end...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2004-10-13)
More Articles from Vaccine Weekly
- AIDS/HIV Vaccine
Correlates of immune protection in HIV-1 infection reviewed - Cancer Vaccine
Future directions for field of oncolytic virotherapy reviewed - Filariasis Vaccine
Subtractive screening identifies Brugia malayi vaccine candidates - Immune Responses
Salmonella vaccine elicit immunity against foreign antigen in neonates - Malaria Vaccine
Long-term T-cell responses induced by Plasmodium peptides - AIDS/HIV Vaccine
Breakthrough infections occur during HIV-1 vaccine trials - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
